NOVN.CH

93.09

-0.34%↓

NOVN.CH

93.09

-0.34%↓

NOVN.CH

93.09

-0.34%↓

NOVN.CH

93.09

-0.34%↓

NOVN.CH

93.09

-0.34%↓

Search

Lonza Group AG

Fermé

SecteurSoins de santé

567.6 0.18

Résumé

Variation du prix de l'action

24h

Actuel

Min

566.6

Max

568

Chiffres clés

By Trading Economics

Revenu

307M

Ventes

3.5B

P/E

Moyenne du Secteur

62.749

38.156

BPA

4.31

Rendement du dividende

0.7

Marge bénéficiaire

8.729

Employés

17,995

EBITDA

764M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+19.22% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.70%

2.50%

Prochains Résultats

23 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-2.7B

39B

Ouverture précédente

567.42

Clôture précédente

567.6

Sentiment de l'Actualité

By Acuity

50%

50%

145 / 375 Classement par Healthcare

Lonza Group AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 juil. 2025, 08:30 UTC

Résultats
Principaux Mouvements du Marché

Lonza Shares Rise After Outlook Lift for Core Business

9 mai 2025, 05:18 UTC

Résultats

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18 févr. 2025, 12:22 UTC

Acquisitions, Fusions, Rachats

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

23 juil. 2025, 08:00 UTC

Market Talk
Résultats

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 juil. 2025, 04:44 UTC

Résultats

Lonza 1H Sales Grew 19% at Constant Currency

23 juil. 2025, 04:43 UTC

Résultats

Lonza 1H Core Ebitda Margin 29.6%

23 juil. 2025, 04:43 UTC

Résultats

Lonza: Margins Will Be Only Minimally Affected

23 juil. 2025, 04:42 UTC

Résultats

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 juil. 2025, 04:42 UTC

Résultats

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 juil. 2025, 04:38 UTC

Résultats

Lonza 1H Net Pft CHF426M

23 juil. 2025, 04:37 UTC

Résultats

Lonza Backs 2025 View for CHI Business

23 juil. 2025, 04:36 UTC

Résultats

Lonza Had Seen CDMO Business Core Ebitda Margin Approaching 30% in 2025

23 juil. 2025, 04:36 UTC

Résultats

Lonza Sees CDMO Business Core Ebitda Margin of 30%-31% in 2025

23 juil. 2025, 04:35 UTC

Résultats

Lonza Had Expected 2025 CDMO Business Sales Growth at Constant Currency of About 20%

23 juil. 2025, 04:35 UTC

Résultats

Lonza Expects 2025 CDMO Business Sales Growth at Constant Currency of 20%-21%

23 juil. 2025, 04:33 UTC

Résultats

Lonza Upgrades 2025 Full-Year CDMO Sales and Margin Outlook

23 juil. 2025, 04:32 UTC

Résultats

Lonza 1H EBITDA CHF1.01B

23 juil. 2025, 04:32 UTC

Résultats

Lonza 1H Core Ebitda CHF1.06B

23 juil. 2025, 04:32 UTC

Résultats

Analysts Saw Lonza 1H Sales at CHF3.51B

23 juil. 2025, 04:32 UTC

Résultats

Analysts Saw Lonza 1H Core Ebitda at CHF1.00B

23 juil. 2025, 04:31 UTC

Résultats

Lonza 1H Sales CHF3.58B

23 juil. 2025, 04:31 UTC

Résultats

Lonza Backs 2025 View

25 juin 2025, 05:27 UTC

Market Talk
Acquisitions, Fusions, Rachats

Lonza Group Looks Well-placed to Benefit From U.S. Pharma Trade Policy -- Market Talk

28 mai 2025, 05:38 UTC

Market Talk

Lonza Looks Like Tariff Winner -- Market Talk

9 mai 2025, 14:45 UTC

Market Talk

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9 mai 2025, 14:42 UTC

Market Talk

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8 avr. 2025, 07:34 UTC

Market Talk

Lonza Well Protected From Tariffs -- Market Talk

29 janv. 2025, 08:11 UTC

Market Talk
Résultats

Lonza's Outlook Looks Positive -- Market Talk

29 janv. 2025, 07:22 UTC

Market Talk
Résultats

Lonza Had a Mixed Year Across Divisions -- Market Talk

29 janv. 2025, 07:11 UTC

Market Talk
Résultats

Lonza's Results Don't Contain Any Surprises -- Market Talk

Comparaison

Variation de prix

Lonza Group AG prévision

Objectif de Prix

By TipRanks

19.22% hausse

Prévisions sur 12 Mois

Moyen 676 CHF  19.22%

Haut 753 CHF

Bas 630 CHF

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

7

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

145 / 375Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.